Portola Pharmaceuticals to Present at Morgan Stanley Global Healthcare Conference
22 Septembre 2015 - 2:46AM
Portola Pharmaceuticals (Nasdaq:PTLA) today announced that William
Lis, chief executive officer, will present at the Morgan Stanley
Global Healthcare Conference on Thursday, September 17, at 11:45
a.m. Eastern Time at the Grand Hyatt New York.
The presentation will be webcast live and available for replay
from Portola's website at www.portola.com in the Investor Relations
section.
About Portola Pharmaceuticals, Inc.
Portola Pharmaceuticals is a biopharmaceutical company
developing product candidates that could significantly advance the
fields of thrombosis and other hematologic diseases. The Company is
advancing its three wholly-owned programs using novel biomarker and
genetic approaches that may increase the likelihood of clinical,
regulatory and commercial success of its potentially life-saving
therapies. These programs include betrixaban, an oral, once-daily
Factor Xa inhibitor being evaluated in the APEX Phase 3 study for
prophylaxis of venous thromboembolism; andexanet alfa, a
recombinant protein designed to reverse the anticoagulant effect in
patients treated with an oral or injectable Factor Xa inhibitor;
and cerdulatinib, a Syk/JAK inhibitor in development to treat
hematologic cancers. Portola's partnered program is focused on
developing selective Syk inhibitors for inflammatory conditions.
For more information, visit www.portola.com and follow the Company
on Twitter @Portola_Pharma.
CONTACT: Investor Contact:
Michele Mantynen
Portola Pharmaceuticals
ir@portola.com
Media Contact:
Julie Normart
W2O Group
jnormart@w2ogroup.com
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Portola Pharmaceuticals (NASDAQ:PTLA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024
Real-Time news about Portola Pharmaceuticals Inc (NASDAQ): 0 recent articles
Plus d'articles sur